CA
NZ
UK
AU
IND
US
The United States and Iran have agreed on a deal to end their war, with both sides declaring the immediate and permanent termination of military operations on all fronts, including in Lebanon, according to Pakistan's prime minister, who has served as a mediator between …
The US sector rotation profile remained highly constructive on June 12, 2026, with leadership broadening across multiple sectors and no areas of the market exhibiting significant relative weakness. The latest Relative Rotation Graph (RRG) shows a healthy distribution of sectors between the Leading and …
The US equity market session on June 12, 2026, demonstrated a healthy and broadly diversified advance across sectors. Unlike recent sessions characterized by sharp rotations between growth and defensive positioning, investors displayed a willingness to allocate capital across multiple segments of the market simultaneously.
CoreWeave Inc (NASDAQ:CRWV) and Astera Labs Inc (NASDAQ:ALAB) were among the biggest movers on Friday after Nasdaq confirmed five new companies will be added to the Nasdaq 100 index as part of its quarterly rebalance, effective June 22.
Intel (NASDAQ: INTC) received a double-tier rating upgrade from Bank of America to Buy, an uncommonly aggressive action that signals a fundamental shift in the brokerage's assessment of the chipmaker's growth prospects. INTC stock surged in response, extending one of the strongest year-to-date performances …
Caribou Biosciences (NASDAQ: CRBU) released initial Phase 1 results for CB-011 from the CaMMouflage trial in relapsed or refractory multiple myeloma, a challenging blood cancer where treatment options become progressively limited after multiple prior lines of therapy.
Caribou Biosciences (NASDAQ: CRBU) presented updated results from the ANTLER Phase 1 trial of vispa-cel at the European Hematology Association 2026 Annual Meeting, delivering efficacy data that reinforces the company's position as a leading allogeneic CAR-T stock in the clinical-stage biotech sector.
Aditxt (NASDAQ: ADTX) shares attracted heightened investor attention following the company's announcement of a $150 million spin-off plan for its Ignite Proteomics subsidiary, with subsequent regulatory filings revealing significant shifts in institutional ownership positions and departures by company insiders.
Two small-cap Nasdaq-listed biotechs disclosed material corporate transactions within the same week, underscoring an active deal environment among early-stage companies seeking to reposition their pipelines and attract institutional investor attention in a selective funding environment.
CEL-SCI (NYSE: CVM) is executing an international commercialisation strategy for its Multikine cancer immunotherapy through a partnership with Saudi Amarox that uses Saudi Arabia's regulatory framework as an entry point into the broader Gulf Cooperation Council healthcare market.
Please wait processing your request...